Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
about
Patient-derived xenograft models of breast cancer and their predictive powerThe future of patient-derived tumor xenografts in cancer treatment.Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograftA novel animal model for locally advanced breast cancer.Establishment of a patient-derived orthotopic osteosarcoma mouse modelPatient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.The efficacy of betulinic acid in triple-negative breast cancer.Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell PopulationSirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expressionCo-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapyProteogenomic integration reveals therapeutic targets in breast cancer xenograftsMolecular markers for breast cancer diagnosis, prognosis and targeted therapy.Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo.Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases.Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.
P2860
Q27026531-EA1C0198-5B12-495A-8563-7A88D0938F95Q33361578-901A44D6-8275-4127-8B55-C10A4FAD07ABQ34566212-97D69004-A4D7-4689-9935-1E374E21C7AEQ35586380-92927DAB-F57A-4BD1-894E-142E40E0A6B8Q35595609-8D9E1955-410E-4F2F-8CD1-82AD9866180EQ35719104-6E8CDC33-2F73-4143-A489-B1F2CA543FD3Q35921330-E9AD9155-F4A3-4951-A9C7-9A21A33B1D64Q36165932-1629BDB6-FC7E-4C78-B1AB-B47363EE5A4DQ36471425-531113BE-D8BD-446C-9327-0A127F2F864DQ36765105-FD4A205E-24B6-4227-8E0B-5E226CA165A9Q37119643-D086734D-25BE-4D41-9313-EAEA721DF752Q37565435-07058B54-F3B0-49B0-8756-64E5903E1E5CQ37580013-7C8A346C-1652-49CA-B61C-DFE7AC661E8EQ37625774-BF42761A-BCFA-47D0-92E1-A1BCBE88B18CQ37645090-D6A55FE8-B1BF-49DD-AE31-D1C1B27211E9Q37688145-20A5DD61-1A4B-4B94-87D7-E07BAA465D46Q37736390-6275A338-F715-467A-A089-4A782A90CDD2Q38236904-51FC9853-46F2-4661-9DC1-8FD377827FD3Q38689944-CDB09D34-94B8-4EED-AF9D-22AB88AD144BQ39000232-FD2CE06B-991E-43E2-8395-BF9D7319CDD4Q39057246-C5148D34-A1F6-4091-907E-CCC69BFAA7C8Q46605325-EF5C9028-7BF8-401F-95C0-226508AA3886Q47137308-736F1BFD-97DA-487C-B0EA-3DBF51284654Q47140067-5F2A4636-15E4-41B2-B992-A356E11F3488Q47141003-3434210B-A7F9-4EF2-9072-F206C9C84D49Q54117329-588C4FFE-1DFC-41E2-96C4-FD8B8652522F
P2860
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@ast
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@en
type
label
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@ast
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@en
prefLabel
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@ast
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@en
P2093
P2860
P50
P356
P1476
Patient-derived xenografts of ...... nd respond to mTOR inhibition.
@en
P2093
Adam L Cohen
Andrea H Bild
Caroline M Piskun
Daniel O Frimannsson
Frederick M Dirbas
Gennadi V Glinsky
Glenn Deng
Haiyu Zhang
Irene L Wapnir
Marc A Coram
P2860
P2888
P356
10.1186/BCR3640
P577
2014-04-07T00:00:00Z
P5875
P6179
1035399591